
Centre debunks viral claim about 104 for blood-on-call service
New Delhi: The Central government has flagged a widely circulating social media post on blood as false and misleading, warning citizens not to fall for it.
The message falsely claims that the government has launched a nationwide 'Blood on Call' service accessible via the number 104.
According to the viral post, calling 104 would allow people to request blood, which would then be delivered within four hours and a 40 km radius.
The message further claims that the service costs Rs 450 per unit of blood and Rs 100 for transportation, urging recipients to share it widely.
'Please forward this message to your friends, relatives and groups. Many lives can be saved from this facility,' the viral post said.
However, the Press Information Bureau (PIB) -- which is also tasked with dispelling misinformation related to government policies -- has clarified that no such scheme exists under the Central government.
In a fact-check alert, PIB stated: 'The Government of India is not running any such scheme. This number is used for various helpline services in some states.'
The helpline number 104 does exist in several states, but it is typically used for general health-related queries, telemedicine consultations, or Covid-19 assistance, and not for any blood delivery service.
The claim has been on the internet since 2022.
The PIB has urged the public to verify any government-related claims from official sources before sharing them.
Spreading misinformation, even if unintentional, can lead to public confusion and misuse of healthcare resources, it warned.
This is not the first time that social media has been used to circulate false medical or health-related claims. The government continues to advise caution, especially with messages that sound too good to be true or lack official verification.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Hindustan Times
31 minutes ago
- Hindustan Times
14 of 18 fresh Covid cases in Haryana from Gurugram, Faridabad, Karnal
Fourteen of the 18 fresh Covid cases that Haryana reported on Monday were from Gurugram, Faridabad and Karnal districts, officials said. According to the state health department, Gurugram and Karnal reported five cases, followed by Faridabad (four), Ambala (two) and one each from Jhajjar and Sonepat. The total number of active cases in the state on Monday was 44, of which 16 were from Gurugram, 10 from Faridabad, nine from Karnal, four from Panchkula, two from Ambala and one each from Sonepat, Jhajjar and Hisar. As of Monday, no patients were hospitalised. Last week, Haryana health minister Arti Singh Rao urged people and healthcare officials to remain vigilant and proactive. She emphasised that the health and safety of every citizen is the government's top priority. Timely action and strict adherence to preventive measures can significantly curb the spread of the virus, she said, adding there was no need to panic.


Business Standard
37 minutes ago
- Business Standard
Biocon gets CDSCO approval for Liraglutide drug substance
Biocon said that it has received an approval from the Drugs Controller General of India (DCGI), under the central drugs standard control organisation (CDSCO), for its Liraglutide drug substance. Additionally, its wholly owned subsidiary, Biocon Pharma, has received CDSCO approval for the Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge). The said approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled type 2 diabetes mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise. The approval was received from the CDSCO under the recently formulated 101 route that enables recognition of approvals granted by established and referenced serious regulatory authorities. Siddharth Mittal, chief executive officer and managing director, Biocon, said: The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes. India has one of the highest number of people with diabetes globally, with estimates exceeding 77 million cases, and expected to rise further. The approval enables us to address a critical need by making this drug available, and aligns with Biocons mission to provide affordable, lifesaving medications to those who need it the most. We are now gearing up to launch the product expeditiously through our commercialization partners in India. Biocon is an innovation-led global biopharmaceutical company focused on improving affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as generic formulations in the U.S. and Europe The companys consolidated net profit surged 154.2% to Rs 344.50 crore on 12.8% jump in net sales to Rs 4,358.10 crore in Q4 FY25 over Q4 FY24. The counter shed 0.45% to end at Rs 334.05 on the BSE.


Mint
41 minutes ago
- Mint
Covid-19 cases in India rise to 4026; Delhi reports 47 new infections, Kerala sees 35 in last 24 hours
India's Covid-19 cases have climbed to 4,026, with 65 new infections reported in the past 24 hours. Delhi registered 47 fresh cases in the past 24 hours, taking its total Covid-19 tally to 483. Kerala saw 35 new infections during the same period. Health authorities are closely monitoring the situation amid the uptick, though hospitalisation rates remain low. More details are being added